NCT00773344View on ClinicalTrials.gov

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

August 31, 2009

Conditions
Solid TumorsBreast Cancer
Interventions
DRUG

Tanespimycin

"Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)"

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

85260

Premiere Oncology Of Arizona, Scottsdale

85724

Arizona Cancer Center, Tucson

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY